Dovato FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
Dovato (dolutegravir and lamivudine) is a combination of the integrase strand transfer inhibitor dolutegravir (Tivicay) and the nucleoside analogue reverse transcriptase inhibitor lamivudine (Epivir) used for the treatment of HIV-1 infection in adults.
- Dovato is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history, or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato.
- The recommended dose of Dovato is one tablet taken once daily, with or without food.
- Common adverse reactions include headache, nausea, diarrhea, insomnia, fatigue, and anxiety.
Development timeline for Dovato
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.